

Advances in Therapeutics

Nicola Charlton MD MPH DBIM, February 2021, R&D



World Health Organization



There is only one way the world can exit this pandemic-and that is through science. We need Diagnostics to detect and limit the spread of this virus, vaccines to provide long-term protection, treatments to save lives in the short-term and social sciences to understand the behavioral and societal implications..



Dr Jeremy Farrar, Director of Wellcome and chair of the WHO R&D blueprint Scientific Advisory Group

Wicked Problems

01

Difficult to solve, no clear solution, not a right or wrong answer but a better or worse

02

Socially complex, difficult to define.

03

Stands astride organizational boundaries and responsibilities

04



Multiple stakeholder ,multi casual

05

Involves behaviour change,




















Theoretical Model of Disease Progression and Targeted Therapies Based on Current Literature

RECOVERY TRIAL-28-day mortality





[Salim Rezaie, Author at REBEL EM - Emergency Medicine Blog](#)

Several vaccines have been approved, and widespread rollout has begun



Company	Type	Doses	Efficacy	Storage	Approvals
Moderna	mRNA	2 	94%	-20°C	    a.o.
Pfizer – BioNTech	mRNA	2 	95%	-70°C	    a.o.
AstraZeneca – Oxford	Modified viral vector	2 	62 – 90%	4°C	  a.o.
Gamalaya (Sputnik V)	Modified viral vector	2 	92%	4°C	 a.o.
Sinopharm I/II	Inactivated virus	2 	79%	4°C	 a.o.
Sinovac	Inactivated virus	2 	50 – 91%	4°C	 a.o.

Protection from viral spread: asymptomatic COVID-19 patients may still spread the disease. Only AstraZeneca has tested and shown a 27 – 59% reduction in viral spread.

Major market dosage availability and total doses




Vaccine progress lowers hospitalisation & mortality



Vaccine acceptance rates may become an issue

If and when a COVID-19 vaccine becomes available, will you get vaccinated?



Thank you!

Contact us



Nicky Charlton, MD, MPH, DBIM

UW R&D Senior Medical Officer, Globals L&H

Nicola_Charlton@swissre.com

+1-856-446-9758

Follow us



Legal notice

©2021 Swiss Re. All rights reserved. You may use this presentation for private or internal purposes but note that any copyright or other proprietary notices must not be removed. You are not permitted to create any modifications or derivative works of this presentation, or to use it for commercial or other public purposes, without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and may change. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for its accuracy or comprehensiveness or its updating. All liability for the accuracy and completeness of the information or for any damage or loss resulting from its use is expressly excluded.

